… trial of patients with HFpEF (NCT03030235), we evaluated whether the SGLT2 inhibitor
dapagliflozin improves the primary endpoint of Kansas City Cardiomyopathy Questionnaire …

… DAPA-HF will determine the efficacy and safety of the SGLT2 inhibitor dapagliflozin,
added to conventional therapy, in a broad spectrum of patients with heart failure and reduced …

… the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial to
… and safety of the SGLT2 inhibitor dapagliflozin in patients with heart failure and a reduced …

… for heart failure or cardiovascular death among patients with heart failure and a left ventricular
… of SGLT2 inhibition may extend to all patients with heart failure, regardless of the left …

… The key finding from these exploratory analyses of patients with heart failure with reduced
ejection fraction was that the effect of the SGLT2 inhibitor dapagliflozin on the primary and …

… SGLT2 inhibition with dapagliflozin reduced the risk of cardiovascular death or HHF to a
greater extent in patients … reductions in cardiovascular death and ACM in patients with HFrEF. …

… of SGLT2 inhibition with dapagliflozin and empagliflozin on fatal events, hospitalisation
for heart failure, … clinical subgroups in a broad spectrum of patients with HFrEF. Our meta-analysis …

… Early dapagliflozin initiation before patient stabilization on the first day of acute heart
failure (AHF) hospitalization was safe, allowing rapid guideline-directed medical therapy (GDMT) …

… SGLT2 inhibitor dapagliflozin can reduce the cardiovascular death/hospitalization for heart
failure (CV death/HHF) in patients … FDA authorized dapagliflozin for adult patients with HFrEF (…

… In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening
heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined …